Nanoparticles can deliver targeted gene therapy in osteoarthritis

Osteoarthritis (OA) is a common joint condition causing pain and cartilage damage, yet there's no way to slow or reverse its progression. RNA-based treatments show promise but need to reach the specific injured areas within the cartilage.

A new study in *Nature Nanotechnology* introduces a specialized nanoparticle system. These particles can accurately deliver disease-modifying gene therapies, like mRNA, directly to lesions after being injected into the joint.

These intelligent nanoparticles are engineered to seek out degenerated cartilage, ensuring the treatment goes precisely where it's needed. Importantly, they can adjust their targeting based on how severe the disease is, which is key as damage varies between individuals and over time.

**Addressing a Gap**

Current delivery methods often miss damaged cartilage. This research fills that gap by developing a system that naturally finds injured cartilage using biochemical signals that arise during OA progression, adapting its aim as severity changes.

Healthy cartilage has a strong negative charge due to molecules called glycosaminoglycans. As cartilage breaks down, it loses these molecules, reducing its negative charge. The researchers leveraged this natural shift to create Matrix-Inverse Targeting (MINT) nanoparticles. Unlike conventional targeting, MINT particles are pushed away by healthy cartilage but pulled towards damaged areas where these molecules are lost.

More severe damage attracts more nanoparticles. Using this "precision-entry" method, the team delivered an mRNA that instructs cartilage cells to produce ghrelin, a protective protein often reduced in OA. They then tested its effectiveness in standard animal models of OA.

**Key Discoveries**

The nanoparticles selectively entered and accumulated in cartilage areas where glycosaminoglycans were lost – precisely the regions that worsen with OA. Significantly, the more severe the cartilage injury, the better the targeting.

When carrying ghrelin mRNA, the nanoparticles slowed cartilage loss, prevented abnormal bone thickening, reduced inflammatory signals, and decreased pain-related nerve activity in mouse models.

**Significance**

This work presents a remarkably simple way to deliver RNA therapies directly to specific OA lesions, automatically adjusting delivery based on damage severity. Because the targeting relies on natural tissue changes, it avoids complex or costly engineering and fits well with existing joint injection practices.

While ghrelin mRNA was used in this study, the system can deliver other RNA-based treatments, offering a broad strategy to slow or even reverse cartilage damage. More widely, this approach provides a blueprint for "disease-responsive" delivery systems that adapt to tissue health in real time, potentially transforming how other conditions are treated.

**Next Steps**

Future efforts will focus on making the treatment's effects last longer and demonstrating that this system can deliver a range of relevant RNA therapies. The team also plans to test the approach in larger animal models that better mimic human knees, helping to advance this technology towards human clinical trials.



Reference
by Mass General Brigham, How 'smart' nanoparticles can deliver targeted gene therapy in osteoarthritis
1 phys.org  Available at https://phys.org/news/2026-01-smart-nanoparticles-gene-therapy-osteoarthritis.html
(Assessed: 20th January 2026)